

Carle F Paul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7259952/publications.pdf>

Version: 2024-02-01

359
papers

20,177
citations

8181

76
h-index

14759

127
g-index

396
all docs

396
docs citations

396
times ranked

12922
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	2.2	17
2	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	3.0	18
3	Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 434-443.	2.4	26
4	Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 139-141.	1.0	2
5	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	1.3	9
6	Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 519-533.	6.5	17
7	Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00672.	1.3	2
8	The biological basis of disease recurrence in psoriasis: a historical perspective and current models. <i>British Journal of Dermatology</i> , 2022, 186, 773-781.	1.5	32
9	Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 602-603.	1.5	6
10	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). <i>British Journal of Dermatology</i> , 2022, 187, 338-352.	1.5	32
11	Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 433-447.	6.7	17
12	Impact of Childhood Onset Psoriasis on Addictive Behaviours, Socioeconomic and Educational Data in Adulthood. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00733.	1.3	2
13	Retrospective Study of Midodrine as a Method of Decreasing Length of Vasopressor Support in the ICU. , 2022, , .		0
14	Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational <i>psoriasis study of health outcomes</i> (<scp>PSoHO</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2087-2100.	2.4	15
15	Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1820-1825.	2.4	19
16	Decision-making factors for the long-term topical treatment of mild-to-moderate plaque psoriasis: TEPPSO, a case-vignette study on clinical practice. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, , .	1.0	0
17	Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 360-368.	1.2	37
18	Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 172-179.	2.4	29

#	ARTICLE	IF	CITATIONS
19	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.5	16
20	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial*. <i>British Journal of Dermatology</i> , 2021, 184, 50-59.	1.5	119
21	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	2.4	14
22	Out-of-pocket expenditures in France to manage psoriasis in adult patients: results from an observational, cross-sectional, non-comparative, multicentre study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 912-918.	2.4	5
23	<i>De novo</i> psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e296-e297.	2.4	26
24	Unmet medical needs in the treatment of atopic dermatitis in infants: An Expert consensus on safety and efficacy of pimecrolimus. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 414-424.	2.6	10
25	Analysis of non-responders to dupilumab in clinical practice: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e192-e194.	2.4	4
26	Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e120-e121.	2.4	6
27	How to assess patient satisfaction regarding physician interaction: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e14702.	1.7	10
28	Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 10-19.	2.4	8
29	Use of Complementary and Alternative Medicines by Patients with Psoriasis: Results from a Study with 2562 Patients. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 285-287.	6.7	1
30	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e308-e311.	2.4	27
31	Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 118.	2.7	3
32	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1101-1112.	27.0	239
33	How Oral Specialists Can Help Diagnose and Manage Extra-Digestive Inflammatory Bowel Disease Complications. <i>Case Reports in Gastroenterology</i> , 2021, 15, 276-281.	0.6	3
34	Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e362-e365.	2.4	24
35	Acrodermatitis enteropathica-like eruption secondary to vitamin and amino acid deficiencies associated with pancreatic tumour. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 133-135.	1.0	0
36	Cutaneous mastocytosis in adults with a serum tryptase level < 20 ng mL ⁻¹ : why we should investigate further. <i>British Journal of Dermatology</i> , 2021, 185, 453-455.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE AD7 Phase 3 randomized trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1543-1552.	2.4	41
38	What instruments should we add to our toolbox for measuring the severity and control of eczema?. <i>British Journal of Dermatology</i> , 2021, 185, 13-14.	1.5	0
39	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021, 385, 142-152.	27.0	173
40	Tapinarof-induced folliculitis: The paradigm of activation of the aryl hydrocarbon signaling pathway. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e37-e38.	1.2	4
41	Dermatose à IgA linéaire sévère compliquée d'une aspergillose invasive. <i>La Presse Médicale Formation</i> , 2021, 2, 303-306.	0.1	0
42	Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. <i>British Journal of Dermatology</i> , 2021, 185, 1052-1054.	1.5	2
43	Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique. <i>Revue Française D'allergologie</i> , 2021, 61, 592-592.	0.2	0
44	First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq. <i>Dermatology</i> , 2021, 237, 338-346.	2.1	5
45	Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2021, , .	2.9	2
46	Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort. <i>Acta Dermato-Venereologica</i> , 2021, , .	1.3	4
47	A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features. <i>British Journal of Dermatology</i> , 2021, , .	1.5	1
48	A Multicentre Randomised Controlled Study Evaluating the Effect of a Standardised Education Programme on Quality of Life, Disease Severity, and Disease Knowledge in Patients with Moderate-To-Severe Psoriasis: The EDUPSO Study. <i>Dermatology</i> , 2021, , 1-10.	2.1	3
49	Efficacy and tolerability of long-pulse Alexandrite laser hair removal for hidradenitis suppurativa. <i>European Journal of Dermatology</i> , 2021, , .	0.6	2
50	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label <sc>OPTIMISE</sc> study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.5	33
51	Positive change in hand care habits using therapeutic patient education in chronic hand eczema. <i>Contact Dermatitis</i> , 2020, 82, 10-17.	1.4	14
52	Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 293-300.	2.4	36
53	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.5	55
54	Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from <sc>UNCOVER</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 301-309.	2.4	22

#	ARTICLE	IF	CITATIONS
55	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
56	Quality of care in atopic dermatitis – a position statement by the European Task Force on Atopic Dermatitis (ETFAD). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e136-e138.	2.4	8
57	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51
58	Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1529-1535.	2.4	11
59	Vascular Nd:YAG laser: a therapeutic alternative for large venous lakes of the oral mucosa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e164-e165.	2.4	1
60	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	2.4	220
61	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
62	The evolving field of Dermatocarcinology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV, UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
63	Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e790-e791.	2.4	7
64	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19
65	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e839-e842.	2.4	22
66	Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. <i>International Journal of Women's Dermatology</i> , 2020, 6, 164-168.	2.0	12
67	532 nm Q-switched laser for the treatment of hyperpigmentation induced by topical tacrolimus. <i>Journal of Cosmetic and Laser Therapy</i> , 2020, 22, 90-92.	0.9	2
68	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e241-e242.	2.4	99
69	Omalizumab in the treatment of adult patients with mastocytosis: A systematic review. <i>Clinical and Experimental Allergy</i> , 2020, 50, 654-661.	2.9	50
70	Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. <i>New England Journal of Medicine</i> , 2020, 382, 706-716.	27.0	189
71	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
72	Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 943-948.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Psoriasis, conception and pregnancy: expectations and perspectives. <i>European Journal of Dermatology</i> , 2020, 30, 2-2.	0.6	0
74	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergology International</i> , 2019, 68, 119-121.	3.3	2
75	Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3. <i>Journal of Dermatological Treatment</i> , 2019, 30, 19-26.	2.2	23
76	Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. <i>Dermatology</i> , 2019, 235, 516-521.	2.1	7
77	Therapeutische Patientenschulungsprogramme und Unterstützung beim Selbstmanagement für Patienten mit Psoriasis – eine systematische Übersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 685-697.	0.8	0
78	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	13.7	198
79	Early necrotic skin lesions after a ABO-incompatible kidney transplantation: The threat of <i>Cunninghamella</i> spp.. <i>Transplant Infectious Disease</i> , 2019, 21, e13173.	1.7	1
80	Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. <i>British Journal of Dermatology</i> , 2019, 180, 1551-1552.	1.5	27
81	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1644-1659.	2.4	85
82	Image Gallery: The vulva: an atypical localization of mastocytosis in adulthood. <i>British Journal of Dermatology</i> , 2019, 181, e33.	1.5	1
83	Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. <i>Clinical and Experimental Dermatology</i> , 2019, 44, e230-e234.	1.3	12
84	Therapeutic patient education and self-management support for patients with psoriasis – a systematic review. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 685-695.	0.8	12
85	Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e338-e341.	2.4	5
86	Frequency of isolated cutaneous involvement in adult mastocytosis: a cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1713-1718.	2.4	6
87	An oral manifestation of IBD: Pyostomatitis vegetans, about two cases. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2019, 120, 375-377.	1.3	1
88	Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome. <i>Osteoporosis International</i> , 2019, 30, 1235-1241.	3.1	8
89	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	2.4	15
90	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	2.4	31

#	ARTICLE	IF	CITATIONS
91	Compounded topical preparations in plaque psoriasis: Still a place for it in 2018?. <i>Dermatologic Therapy</i> , 2019, 32, e12780.	1.7	1
92	Prioritizing topics in guideline development: results of a two-phase online survey of dermatologist members of the <sc>EADV</sc>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 227-233.	2.4	5
93	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. <i>Journal of Investigative Dermatology</i> , 2019, 139, 31-37.	0.7	55
94	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 70-79.e3.	1.2	77
95	Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from <sc>EPIDEPSO</sc>. <i>British Journal of Dermatology</i> , 2019, 180, 397-403.	1.5	16
96	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 266-276.e5.	1.2	117
97	Infectious risk of biological drugs vs. traditional systemic treatments in moderate-to-severe psoriasis: a cohort analysis in the French insurance database. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 436-449.	1.9	10
98	Focal facial hyperhidrosis associated with internal carotid artery dissection successfully treated with botulinum toxin A. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e314-e316.	2.4	1
99	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. <i>British Journal of Dermatology</i> , 2018, 178, 1199-1203.	1.5	25
100	Efficacy of ustekinumab in palmoplantar pustulosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e204-e206.	2.4	6
101	Stabilization of microtubules restores barrier function after cytokine-induced defects in reconstructed human epidermis. <i>Journal of Dermatological Science</i> , 2018, 91, 87-96.	1.9	10
102	Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study. <i>British Journal of Dermatology</i> , 2018, 178, e33-e34.	1.5	7
103	Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 231-233.	1.3	11
104	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). <i>British Journal of Dermatology</i> , 2018, 178, 674-681.	1.5	80
105	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 68-72.	2.4	20
106	Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. <i>European Journal of Dermatology</i> , 2018, 28, 356-363.	0.6	18
107	Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease. <i>Dermatology</i> , 2018, 234, 23-30.	2.1	5
108	Ixekizumab or secukinumab in psoriasis: what difference does it make?. <i>British Journal of Dermatology</i> , 2018, 178, 1003-1005.	1.5	23

#	ARTICLE	IF	CITATIONS
109	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , 2018, 194, 75-79.	3.2	10
110	Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1920-1929.	2.4	10
111	Characterization and Outcomes of Disease Progression in 52 Patients Treated with <i>BRAF</i> + MEK Inhibitors for Advanced Melanoma. <i>Dermatology</i> , 2018, 234, 92-98.	2.1	5
112	Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 200-206.	0.8	15
113	Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e73-e74.	2.4	15
114	Conflicts of interest and authorship of industry-sponsored publications. <i>British Journal of Dermatology</i> , 2017, 176, 200-203.	1.5	7
115	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
116	Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <sc>JUNCTURE</sc> trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 847-856.	2.4	44
117	A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1176-1182.	2.4	10
118	Systemic allergic contact dermatitis caused by methyl aminolaevulinate in a patient with keratosis-ichthyosis-deafness syndrome. <i>Contact Dermatitis</i> , 2017, 76, 190-192.	1.4	12
119	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 405-411.	6.7	24
120	Non-surgical treatments for hidradenitis suppurativa: A systematic review. <i>Annales De Chirurgie Plastique Et Esthetique</i> , 2017, 62, 274-294.	0.6	27
121	Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1491-1496.	2.4	47
122	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. <i>British Journal of Dermatology</i> , 2017, 177, 1014-1023.	1.5	155
123	Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2046-2054.	2.4	30
124	Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e423-e424.	2.4	7
125	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet, The</i> , 2017, 389, 2031-2040.	13.7	438
126	Azathioprine Hypersensitivity Syndrome: Two Cases of Febrile Neutrophilic Dermatoses Induced by Azathioprine. <i>Case Reports in Dermatology</i> , 2017, 9, 6-11.	0.8	10

#	ARTICLE	IF	CITATIONS
127	Authorship selection in industry-sponsored publications of dermatology clinical trials. <i>British Journal of Dermatology</i> , 2017, 176, 1669-1671.	1.5	9
128	Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study. <i>British Journal of Dermatology</i> , 2017, 176, 1195-1203.	1.5	37
129	Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 115-121.	1.8	16
130	European S3â€“Guideline on the systemic treatment of psoriasis vulgaris â€“ Update Apremilast and Secukinumab â€“ <sc>EDF</sc> in cooperation with <sc>EADV</sc> and <sc>IPC</sc>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	2.4	116
131	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , 2017, 105, 219-225.	2.9	28
132	Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling. <i>Circulation</i> , 2017, 136, 1037-1048.	1.6	204
133	Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSOâ€“ABLE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 119-126.	2.4	92
134	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 294-303.	2.4	12
135	Immunohistochemical staining for diagnosis of cutaneous mastocytosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e160-e162.	2.4	5
136	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 432-440.e17.	1.2	111
137	Palmar erythema: inaugural manifestation of HIV infection. <i>European Journal of Dermatology</i> , 2017, 27, 668-669.	0.6	0
138	Efficacy of hospital inpatient topical treatment for severe adult atopic dermatitis: a retrospective study of 56 patients. <i>European Journal of Dermatology</i> , 2017, 27, 418-419.	0.6	2
139	Botulinum Toxin A: An Effective Treatment for Linear Immunoglobulin A Bullous Dermatitis Located in the Axillae. <i>Acta Dermato-Venereologica</i> , 2016, 96, 122-123.	1.3	9
140	Active tuberculosis in psoriasis patients treated with <sc>TNF</sc> antagonists: a French nationwide retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1336-1341.	2.4	16
141	Antitumour necrosis factor-Î± therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. <i>British Journal of Dermatology</i> , 2016, 174, 667-670.	1.5	18
142	Calculation of cutâ€“off values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1 for defining moderate, significant and extensive types of pemphigus. <i>British Journal of Dermatology</i> , 2016, 175, 142-149.	1.5	68
143	Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study. <i>Dermatology</i> , 2016, 232, 550-557.	2.1	1
144	CaractÃ©ristiques clinico-biologiques des mastocytoses suivies en rhumatologie. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, A136-A137.	0.0	0

#	ARTICLE	IF	CITATIONS
145	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 77-82.e7.	1.2	96
146	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 133-141.	2.9	8
147	Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1753-1759.	2.4	42
148	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016, 175, 273-286.	1.5	378
149	Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1038-1044.	1.2	35
150	Photo-induced graft-versus-host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2016, 32, 291-295.	1.5	2
151	Improvement of Microstomia in Scleroderma after Carbon Dioxide Laser Treatment. <i>Case Reports in Dermatology</i> , 2016, 8, 142-150.	0.8	15
152	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 291-304.	3.4	119
153	Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. <i>British Journal of Dermatology</i> , 2016, 175, 636-638.	1.5	26
154	Acquired perforating dermatosis associated with sorafenib therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 328-330.	2.4	7
155	<i>Staphylococcus aureus</i> density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1272-1274.e3.	2.9	146
156	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
157	Enzalutamide induced acute generalized exanthematous pustulosis. <i>Journal of Dermatological Case Reports</i> , 2016, 10, 35-38.	1.1	14
158	Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2002-2010.	2.4	139
159	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). <i>British Journal of Dermatology</i> , 2015, 173, 1387-1399.	1.5	384
160	Academic mentorship in dermatology. <i>British Journal of Dermatology</i> , 2015, 173, 1113-1114.	1.5	3
161	Validation of Treatment Escalation as a Definition of Atopic Eczema Flares. <i>PLoS ONE</i> , 2015, 10, e0124770.	2.5	24
162	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0145076.	2.5	42

#	ARTICLE	IF	CITATIONS
163	Defects of corneocyte structural proteins and epidermal barrier in atopic dermatitis. <i>Biological Chemistry</i> , 2015, 396, 1163-1179.	2.5	24
164	European S3â€“Guidelines on the systemic treatment of psoriasis vulgaris â€“ Update 2015 â€“ Short version â€“ <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
165	Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. <i>Value in Health</i> , 2015, 18, A429.	0.3	0
166	Development and psychometric validation of the REF lective evaluation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaqueâ€“type psoriasis severity and treatment efficacy for patients and clinicians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 498-506.	2.4	10
167	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 306-315.	2.6	71
168	Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 242-248.	1.2	222
169	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	2.2	50
170	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and Tj ETQq0 0,0,rgBT /Overlock 10	13.7	719
171	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 992-1002.	1.2	162
172	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	27.0	656
173	Angiolymphoid hyperplasia with eosinophilia treated with low-dose methotrexate. <i>JAAD Case Reports</i> , 2015, 1, 342-344.	0.8	5
174	GRAPPA Fellows Symposium Adjacent to the Swiss Psoriasis Day, Geneva, 2014: A Meeting Report. <i>Journal of Rheumatology</i> , 2015, 42, 1014-1015.	2.0	1
175	Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (<scp>JUNCTURE</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1082-1090.	2.4	254
176	Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 224-231.	2.4	31
177	Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation. <i>British Journal of Dermatology</i> , 2014, 170, 1327-1335.	1.5	14
178	Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients. <i>Dermatology</i> , 2014, 229, 183-189.	2.1	16
179	Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 33-39.	2.4	6
180	Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 17-26.	2.4	72

#	ARTICLE	IF	CITATIONS
181	Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 3-12.	2.4	25
182	Risk factors, diagnosis and management of psoriatic arthritis: systematic literature reviews and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-2.	2.4	0
183	Bleomycin hydrolase downregulation in lesional skin of adult atopic dermatitis patients is independent of FLG gene mutations. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1459-1461.e7.	2.9	16
184	Consensus recommendations for the treatment of basal cell carcinomas in <sc>G</sc> orlin syndrome with topical methylaminolaevulinate-photodynamic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 626-632.	2.4	44
185	Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1235-1244.	2.4	20
186	Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. <i>Journal of Dermatological Treatment</i> , 2014, 25, 75-77.	2.2	8
187	High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness <i>in vivo</i>: a prospective validation study. <i>British Journal of Dermatology</i> , 2014, 171, 799-805.	1.5	39
188	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <sc>TRANSIT</sc> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
189	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
190	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1670-1675.	2.4	75
191	Point prevalence and risk factors for food allergy in a cohort of 386 children with atopic dermatitis attending a multidisciplinary dermatology/paediatric allergy clinic. <i>European Journal of Dermatology</i> , 2014, 24, 63-69.	0.6	17
192	Knockdown of Filaggrin in a Three-Dimensional Reconstructed Human Epidermis Impairs Keratinocyte Differentiation. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2938-2946.	0.7	111
193	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
194	Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 12-29.	2.4	248
195	Alcohol consumption and psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 30-35.	2.4	121
196	CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. <i>Journal of Dermatological Science</i> , 2013, 69, 105-113.	1.9	15
197	Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1094-1102.	2.9	212
198	Buprenorphine-induced linear IgA bullous dermatosis -œœdown the rail. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e106-e107.	1.2	2

#	ARTICLE	IF	CITATIONS
199	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013, 168, 402-411.	1.5	118
200	Is conjunctival mucous involvement a marker of severity in pemphigus vulgaris?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 520-521.	2.4	6
201	Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 36-46.	2.4	194
202	Efficacy, Safety and Tolerability of an Optimized Avulsion Technique with Onyster® (40% Urea) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 Clinically Infected Nail in Toenail Onychomycosis: a Randomized Evaluator-Blinded Controlled Study. <i>Dermatology</i> , 2013, 226, 5-12.	2.1	24
203	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 1080-1087.	1.5	77
204	A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in Dermatophytic Onychomycosis. <i>Dermatology</i> , 2013, 227, 157-164.	2.1	16
205	Late-Onset X-Linked Dominant Protoporphyrria: An Etiology of Photosensitivity in the Elderly. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1688-1690.	0.7	11
206	Nickel-Induced Systemic Contact Dermatitis and Intratubal Implants. <i>Dermatitis</i> , 2013, 24, 35-36.	1.6	26
207	Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 2-11.	2.4	46
208	Incidence and risk factors for treatment failure with <i>infliximab</i> in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1323-1324.	2.4	5
209	Cardiovascular morbidity, risk of cancer and alcohol abuse in psoriasis: systematic literature reviews and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1-1.	2.4	5
210	Socioeconomic outcomes following spinal cord injury and the role of no-fault compensation: longitudinal study. <i>Spinal Cord</i> , 2013, 51, 919-925.	1.9	25
211	Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1423.	1.4	42
212	Prognostic Factors of Paraneoplastic Pemphigus. <i>Archives of Dermatology</i> , 2012, 148, 1165.	1.4	125
213	Why Statistics Matter: Limited Inter-Rater Agreement Prevents Using the Psoriasis Area and Severity Index as a Unique Determinant of Therapeutic Decision in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2171-2175.	0.7	52
214	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012, 22, 762-769.	0.6	25
215	Towards global consensus on outcome measures for atopic eczema research: results of the <i>HOME II</i> meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1111-1117.	5.7	169
216	Simultaneous cutaneous infection due to <i>P</i> <i>aecilomyces lilacinus</i> and <i>A</i> <i>lternaria</i> in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2012, 14, E156-60.	1.7	12

#	ARTICLE	IF	CITATIONS
217	Quantification of <i>Demodex folliculorum</i> by <i>scp</i> -PCR in rosacea and its relationship to skin innate immune activation. <i>Experimental Dermatology</i> , 2012, 21, 906-910.	2.9	171
218	New topical drug development in atopic dermatitis: a place for hope. <i>British Journal of Dermatology</i> , 2012, 166, 711-711.	1.5	0
219	Psoriasis: rationale for targeting interleukin-17. <i>British Journal of Dermatology</i> , 2012, 167, 717-724.	1.5	120
220	Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. <i>British Journal of Dermatology</i> , 2012, 167, 1138-1144.	1.5	91
221	Contact Photoallergy to Isothipendyl Chlorhydrate. <i>Dermatology</i> , 2012, 224, 289-291.	2.1	12
222	Update on the epidermal differentiation complex. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 1517.	3.0	125
223	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 448-455.	2.4	21
224	<i>In vivo</i> quantification of epidermis pigmentation and dermis papilla density with reflectance confocal microscopy: variations with age and skin phototype. <i>Experimental Dermatology</i> , 2012, 21, 281-286.	2.9	50
225	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , 2012, 167, 643-648.	1.5	31
226	Topical treatment and phototherapy in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, iii-iv.	2.4	1
227	Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1-10.	2.4	56
228	Efficacy of Psoralen UV-A therapy vs. Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 11-21.	2.4	60
229	Carcinogenic risks of Psoralen UV-A therapy and Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 22-31.	2.4	246
230	Ocular damage in patients with psoriasis treated by Psoralen UV-A therapy or Narrow band UVB therapy: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 32-35.	2.4	13
231	Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 36-46.	2.4	34
232	Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 47-51.	2.4	53
233	Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 52-60.	2.4	42
234	Adherence to topical treatment in psoriasis: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 61-67.	2.4	161

#	ARTICLE	IF	CITATIONS
235	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2012, 168, no-no.	1.5	199
236	Blue nevus with satellitosis mimicking melanoma. Contribution of dermoscopy and reflectance confocal microscopy. <i>Journal of Dermatological Case Reports</i> , 2012, 6, 54-6.	1.1	7
237	Management of Autoimmune Bullous Diseases in France: A Nationwide Network of 30 Centers. <i>Dermatologic Clinics</i> , 2011, 29, 659-662.	1.7	1
238	Interferon Alpha and Pamidronate in Osteoporosis with Fracture Secondary to Mastocytosis. <i>American Journal of Medicine</i> , 2011, 124, 776-778.	1.5	41
239	High-resolution magnetic resonance imaging in study of the skin: Normal patterns. <i>European Journal of Radiology</i> , 2011, 80, e176-e181.	2.6	21
240	Efficacy and tolerability of methotrexate in severe childhood alopecia areata. <i>British Journal of Dermatology</i> , 2011, 165, 407-410.	1.5	69
241	Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 1332-1336.	1.5	23
242	Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 861-864.	2.4	25
243	Joint clinical and pathological review meetings improve patient care: a prospective evaluation in dermatology. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 928-932.	2.4	1
244	Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1238-1240.	2.4	59
245	Use of conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1-1.	2.4	2
246	Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 2-11.	2.4	70
247	Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 12-18.	2.4	135
248	Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 19-27.	2.4	100
249	Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 28-33.	2.4	51
250	Traitement du psoriasis en pratique pour le rhumatologue. <i>Revue Du Rhumatisme Monographies</i> , 2011, 78, 145-151.	0.0	2
251	Cytophagic Histiocytic Panniculitis after H1N1 Vaccination: A Case Report and Review of the Cutaneous Side Effects of Influenza Vaccines. <i>Dermatology</i> , 2011, 222, 217-220.	2.1	6
252	Hornerin is a component of the epidermal cornified cell envelopes. <i>FASEB Journal</i> , 2011, 25, 1567-1576.	0.5	80

#	ARTICLE	IF	CITATIONS
253	Prevalence and Risk Factors for Xerosis in the Elderly: A Cross-Sectional Epidemiological Study in Primary Care. <i>Dermatology</i> , 2011, 223, 260-265.	2.1	107
254	Deimination of Human Filaggrin-2 Promotes Its Proteolysis by Calpain 1. <i>Journal of Biological Chemistry</i> , 2011, 286, 23222-23233.	3.4	70
255	Albright hereditary osteodystrophy: report of a particular clinical phenotype caused by a novel <i>GNAS</i> mutation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 974-975.	2.4	3
256	Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. <i>American Journal of Hematology</i> , 2010, 85, 921-925.	4.1	98
257	Psoriasis evaluation in clinical practice: systematic review and expert opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1-1.	2.4	2
258	Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 2-9.	2.4	62
259	What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 10-16.	2.4	229
260	What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 17-22.	2.4	114
261	Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 23-30.	2.4	119
262	Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 31-35.	2.4	124
263	Psoriasis: an epidemiological evaluation of disease burden in 590 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1075-1082.	2.4	87
264	Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1171-1175.	2.4	33
265	Purpuric lesions induced by UVA1 spectrum (340-400nm) phototesting in an adult with persistent and severe hydroa vacciniforme. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2010, 26, 104-106.	1.5	2
266	Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients. <i>British Journal of Dermatology</i> , 2010, 162, 830-834.	1.5	37
267	Iatrogenic adrenal insufficiency associated with calcipotriol/betamethasone topical combination in psoriasis. <i>Clinical and Experimental Dermatology</i> , 2010, 35, e167-e168.	1.3	7
268	Childhood chilblains is an uncommon and invalidant disease. <i>Archives of Disease in Childhood</i> , 2010, 95, 567-568.	1.9	13
269	Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. <i>Acta Dermato-Venereologica</i> , 2010, 90, 12-17.	1.3	51
270	Efficacy of Ustekinumab in Palmoplantar Psoriasis. <i>Dermatology</i> , 2010, 221, 321-323.	2.1	29

#	ARTICLE	IF	CITATIONS
271	Incidence of Auto-Immune Pemphigus in the Midi-Pyrénées Region in 2002-2006. <i>Dermatology</i> , 2010, 220, 97-102.	2.1	10
272	Dermatite atopique de l'enfant : quand penser à l'allergie alimentaire ?. <i>Revue Francaise D'allergologie</i> , 2010, 50, S14-S20.	0.2	2
273	Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: A prospective observational study. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 945-949.	1.2	69
274	Cutaneous T Cell Lymphoma Complicating Severe Atopic Dermatitis. <i>Dermatology</i> , 2009, 218, 168-171.	2.1	16
275	Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 524-531.	1.6	15
276	Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion. <i>Joint Bone Spine</i> , 2009, 76, 540-546.	1.6	8
277	Diagnosis of peripheral psoriatic arthritis: Recommendations for clinical practice based on data from the literature and experts opinion. <i>Joint Bone Spine</i> , 2009, 76, 532-539.	1.6	19
278	Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. <i>British Journal of Dermatology</i> , 2009, 160, 622-628.	1.5	121
279	Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. <i>British Journal of Dermatology</i> , 2009, 161, 660-663.	1.5	56
280	CONSORT adoption and quality of reporting of randomized controlled trials: a systematic analysis in two dermatology journals. <i>British Journal of Dermatology</i> , 2009, 161, 1159-1165.	1.5	64
281	Cancer Risk Evaluation in Psoriasis: In Search of the Holy Grail?. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2547-2549.	0.7	3
282	Milia complicating bullous polymorphic light eruption. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 51-52.	1.5	2
283	Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 801-806.	5.7	134
284	Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor- α blocking agents: two cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 967-968.	2.4	22
285	Moderate to severe psoriasis: from topical to biological treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1324-1326.	2.4	14
286	Photodistribution of Blue-Gray Hyperpigmentation After Amiodarone Treatment. <i>Archives of Dermatology</i> , 2008, 144, 92-6.	1.4	44
287	Distal Madelung-Launois-Bensaude disease: an unusual differential diagnosis of acromelic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 351-3.	0.8	4
288	Potential New Indications of Topical Calcineurin Inhibitors. <i>Dermatology</i> , 2007, 215, 45-54.	2.1	68

#	ARTICLE	IF	CITATIONS
289	An Update on the Safety and Tolerability of Pimecrolimus Cream 1%: Evidence from Clinical Trials and Post-Marketing Surveillance. <i>Dermatology</i> , 2007, 215, 27-44.	2.1	40
290	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	2.1	30
291	Diagnostic du rhumatisme psoriasique de forme pŕŕiphŕrique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir dŕune analyse systŕmatique de la littŕature et de lŕopinion dŕexperts. <i>O.0 Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 15-22.	0.0	4
292	Pronostic et suivi du rhumatisme psoriasique de forme pŕŕiphŕrique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir dŕune analyse systŕmatique de la littŕature et de lŕopinion dŕexperts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 23-30.	0.0	0
293	Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 808-816.	0.7	233
294	Les traitements mŕdicamenteux (hors biothŕrapie) dans la prise en charge de patients atteints de rhumatisme psoriasique pŕŕiphŕrique : ŕlaboration de recommandations pour la pratique clinique, ŕ partir dŕune analyse systŕmatique de la littŕature et de lŕopinion dŕexperts. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 31-38.	0.0	0
295	A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. <i>British Journal of Dermatology</i> , 2007, 157, 954-959.	1.5	72
296	Carbimazole-induced juvenile dermatomyositis. <i>British Journal of Dermatology</i> , 2007, 158, 071106220718008-???	1.5	8
297	Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. <i>Journal of Dermatology</i> , 2007, 34, 231-236.	1.2	18
298	Cellular phone addiction and allergic contact dermatitis to nickel. <i>Contact Dermatitis</i> , 2007, 57, 130-131.	1.4	34
299	Contact dermatitis to hydrolyzed wheat protein. <i>Contact Dermatitis</i> , 2007, 57, 283-284.	1.4	18
300	Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 375-381.	5.7	56
301	Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel®, SDZ ASM 981): impact on quality of life and healthŕelated quality of life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 248-254.	2.4	30
302	Conflicts of Interest in Dermatology. <i>Acta Dermato-Venereologica</i> , 2006, 86, 485-497.	1.3	28
303	Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years. <i>Pediatrics</i> , 2006, 117, e118-e128.	2.1	109
304	Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. <i>British Journal of Dermatology</i> , 2005, 152, 1219-1227.	1.5	53
305	Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2005, 152, 1296-1303.	1.5	44
306	Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 247-253.	1.2	78

#	ARTICLE	IF	CITATIONS
307	Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: A two-year study. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 240-246.	1.2	101
308	Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: A randomized, investigator-blind comparison. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 602-609.	1.2	64
309	Chronic Dermatofungal Infections of the Foot as Risk Factors for Acute Bacterial Cellulitis of the Leg: A Case-Control Study. <i>Dermatology</i> , 2004, 209, 301-307.	2.1	161
310	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , 2004, 150, 96-102.	1.5	136
311	Cyclosporin in psoriasis clinical practice: an international consensus statement. <i>British Journal of Dermatology</i> , 2004, 150, 11-23.	1.5	132
312	Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. <i>International Journal of Dermatology</i> , 2004, 43, 978-983.	1.0	33
313	Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2004, 15, 169-178.	2.2	103
314	Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study. <i>Journal of Investigative Dermatology</i> , 2003, 120, 211-216.	0.7	328
315	Treating Severe Psoriasis: How to Navigate Safely Between Scylla and Charybdis?. <i>Journal of Investigative Dermatology</i> , 2003, 121, ix-x.	0.7	3
316	Importance of trial design in studies using high-dose intravenous immunoglobulin: reply from authors. <i>British Journal of Dermatology</i> , 2003, 148, 1285-1286.	1.5	1
317	Terbinafine in the Treatment of Trichophyton Tinea Capitis: A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study. <i>Pediatrics</i> , 2002, 109, 602-607.	2.1	85
318	Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis. <i>Dermatology</i> , 2002, 205, 383-388.	2.1	46
319	One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. <i>Journal of Dermatological Treatment</i> , 2002, 13, 39-40.	2.2	8
320	Long-term Effectiveness of Treatment With Terbinafine vs Itraconazole in Onychomycosis. <i>Archives of Dermatology</i> , 2002, 138, 353-7.	1.4	181
321	Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. <i>Pediatrics</i> , 2002, 110, e2-e2.	2.1	315
322	Effect of Terbinafine on the Pharmacokinetics and Pharmacodynamics of Desipramine in Healthy Volunteers Identified as Cytochrome P450 2D6 (CYP2D6) Extensive Metabolizers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1211-1218.	2.0	53
323	Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 110, 277-284.	2.9	250
324	Terbinafine (Lamisil®) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. <i>British Journal of Dermatology</i> , 2002, 146, 254-260.	1.5	35

#	ARTICLE	IF	CITATIONS
325	A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to <i>Microsporum</i> species. <i>British Journal of Dermatology</i> , 2002, 146, 816-823.	1.5	80
326	A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2002, 147, 518-522.	1.5	111
327	Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. <i>British Journal of Dermatology</i> , 2002, 147, 1241-1243.	1.5	31
328	Topical tacrolimus and pimecrolimus are not associated with skin atrophy: reply from author. <i>British Journal of Dermatology</i> , 2002, 146, 343-343.	1.5	0
329	Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: A 2-year cohort study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 643-651.	1.2	142
330	The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. <i>British Journal of Dermatology</i> , 2001, 144, 507-513.	1.5	232
331	Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. <i>British Journal of Dermatology</i> , 2001, 144, 967-972.	1.5	123
332	Long-term efficacy of antifungals in toenail onychomycosis: a critical review. <i>British Journal of Dermatology</i> , 2001, 145, 446-452.	1.5	39
333	One week terbinafine 1% cream (Lamisil®) once daily is effective in the treatment of interdigital tinea pedis: a vehicle controlled study. <i>Medical Mycology</i> , 2001, 39, 335-340.	0.7	38
334	Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids. <i>FEBS Journal</i> , 2000, 267, 5849-5857.	0.2	65
335	Ascomycins: promising agents for the treatment of inflammatory skin diseases. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 69-77.	4.1	65
336	Enhanced surveillance of HIV infections in New Zealand, 1996-1998. <i>New Zealand Medical Journal</i> , 2000, 113, 390-4.	0.5	10
337	Letter to <i>Dermatology</i> . <i>Dermatology</i> , 1999, 198, 320-323.	2.1	12
338	Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. <i>British Journal of Dermatology</i> , 1999, 141, 283-291.	1.5	124
339	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. <i>British Journal of Dermatology</i> , 1999, 141, 259-263.	1.5	15
340	EMLA cream as a topical anesthetic for the repeated mechanical debridement of venous leg ulcers: A double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 208-213.	1.2	68
341	Epidermodysplasia verruciformis-like eruption complicating human immunodeficiency virus infection. <i>British Journal of Dermatology</i> , 1998, 139, 122-127.	1.5	66
342	Ascomycins in dermatology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 1998, 17, 256-259.	1.6	19

#	ARTICLE	IF	CITATIONS
343	Cutaneous Effects of Granulocyte Colony-Stimulating Factor in Healthy Volunteers. Archives of Dermatology, 1998, 134, 111-112.	1.4	22
344	Dermatite atopique Traitements actuels et traitements d'avenir. Revue Francaise D'allergologie Et D'immunologie Clinique, 1997, 37, 361-366.	0.1	0
345	Screening for hepatitis B carriers: A perspective from New Zealand. Australian and New Zealand Journal of Medicine, 1997, 27, 698-705.	0.5	1
346	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Archives of Dermatology, 1997, 133, 867-871.	1.4	49
347	Drug-induced linear IgA disease: target antigens are heterogeneous. British Journal of Dermatology, 1997, 136, 406-411.	1.5	44
348	More on cutaneous reactions to recombinant cytokine therapy. Journal of the American Academy of Dermatology, 1996, 35, 650.	1.2	15
349	Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. British Journal of Dermatology, 1996, 134, 710-714.	1.5	248
350	Oral contraceptive use and risk of breast cancer in older women (New Zealand). Cancer Causes and Control, 1995, 6, 485-491.	1.8	2
351	Hyperkeratotic spicules and monoclonal gammopathy. Journal of the American Academy of Dermatology, 1995, 33, 346-351.	1.2	41
352	Heterosexual behaviour and HIV risk in New Zealand: data from a national survey. Australian Journal of Public Health, 1995, 19, 13-18.	0.2	21
353	Infection Due to Klebsiella rhinoscleromatis in Two Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1993, 16, 441-442.	5.8	28
354	Alternative Splicing Is Responsible for the Presence of Two Tissue Factor mRNA Species in LPS Stimulated Human Monocytes. Thrombosis and Haemostasis, 1992, 67, 272-276.	3.4	25
355	Chromoblastomycosis with malignant transformation and cutaneous-synovial secondary localization. The potential therapeutic role of itraconazole. Medical Mycology, 1991, 29, 313-316.	0.7	13
356	Oral contraceptives and risk of breast cancer. International Journal of Cancer, 1990, 46, 366-373.	5.1	61
357	No new evidence on the cervical cancer study. New Zealand Medical Journal, 1990, 103, 581-3.	0.5	2
358	Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.. BMJ: British Medical Journal, 1989, 299, 759-762.	2.3	74
359	The New Zealand cervical cancer study: could it happen again?. BMJ: British Medical Journal, 1988, 297, 533-539.	2.3	20